Skip to content

Author

Gaurav Gupta

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Open access Sep 2026

Nirsevimab for RSV Prevention in India: Economic Viability and Implementation Pathways for National Introduction: A Review

Respiratory syncytial virus (RSV) causes substantial morbidity and mortality in Indian infants, with an estimated 800,000–1.2 million annual hospitalizations. Nirsevimab, a long-acting monoclonal antibody providing single-dose seasonal protection, has recently become available in India but remains cost-prohibitive for...

Gaurav Gupta · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.